Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Juvéderm VYCROSS is a proprietary cross-linking technology developed by Allergan Aesthetics (an AbbVie company) for its collection of hyaluronic acid (HA) dermal fillers. The technology combines 90% low molecular weight HA with 10% high molecular weight HA to create a smoothly integrated, long-lasting gel that provides structural support and hydration to facial tissues. Most products in the VYCROSS collection also contain 0.3% lidocaine to minimize discomfort during the injection process. The collection includes specialized formulations such as Voluma for cheek and chin volume, Volbella for lip augmentation and fine lines, and Volux for jawline definition. These products function as injectable implants that add volume to tissue and help retain moisture, with results typically lasting between 6 to 24 months depending on the specific product and treatment area.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Juvéderm VYCROSS.